Advanced Prostate CancerPROCEEDNCT01306890
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
An observational study of Advanced Prostate Cancer and Prostatic Neoplasms, run by Dendreon at 333 sites in United States.
Trial summary
The purpose of this study is to further quantify the risk of cerebrovascular events (CVEs) following sipuleucel-T (PROVENGE®) therapy, and to follow all subjects for survival. Read more about this study
- Who is it for?
- Ages 18 years and older, men only
- Conditions the study is for
- Advanced Prostate Cancer, Prostatic Neoplasms
- What is being tested?
- sipuleucel-T
- How many people
- 1,976 participants
- Where
- 333 sitesUnited States
- Study dates
- 27 Jan 2011to 17 Jan 2017
- Phase
- Observational
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Men only
- No healthy volunteers
- Adult, Older adult
Study population: Men at least 18 years of age that have advanced prostate cancer that is treated with sipuleucel-T
Who may be able to join
- subjects must be at least 18 years of age
- subjects with advanced prostate cancer who will receive sipuleucel-T or who underwent their first leukapheresis for manufacture of sipuleucel-T ≤ 6 months prior to enrollment
- subjects must understand and sign an informed consent form
Who cannot join
- none
Trial locations and contacts
333 sites in 1 country.
300 sites in 1 country
United States300 sites
Hendrick Medical Center / Hendrick Cancer Center
Abilene, Texas, 79601
Texas Oncology-Abilene
Abilene, Texas, 79606-5208
New York Oncology Hematology, P.C.
Albany, New York, 12206
New York Oncology Hematology, P.C.
Albany, New York, 12208
New Mexico Oncology Hematology Consultants, LTD
Albuquerque, New Mexico, 87109
Georgia Cancer Specialists - Alpharetta
Alpharetta, Georgia, 30005
Cancer Centers of Southwest Oklahoma
Altus, Oklahoma, 73521
McFarland Clinic, PC
Ames, Iowa, 50010
Asheville Hematology & Oncology
Asheville, North Carolina, 28803
Georgia Cancer Specialists - Athens
Athens, Georgia, 30606
Georgia Cancer Specialists - Emory Midtown
Atlanta, Georgia, 30308
Midtown Urology
Atlanta, Georgia, 30308
Atlanta Hematology Oncology Associates
Atlanta, Georgia, 30309-1710
Peachtree Hematology-Oncology Consultants, PC
Atlanta, Georgia, 30318
Piedmont West
Atlanta, Georgia, 30318
Emory University Hospital, The Emory Clinic, Winship Cancer Institute
Atlanta, Georgia, 30322
Georgia Urology, PA
Atlanta, Georgia, 30342
Augusta Oncology Associates, PC
Augusta, Georgia, 30901
Rocky Mountain Cancer Centers
Aurora, Colorado, 80012
Northwest Georgia Oncology Centers, P.C.
Austell, Georgia, 30106
Texas Oncology - Austin Midtown
Austin, Texas, 78705
Texas Oncolocy - South Austin
Austin, Texas, 78745
Texas Oncology - Austin North
Austin, Texas, 78758
Mount Sinai Comprehensive Cancer Center
Aventura, Florida, 33180
Urologic Consultants of SE PA
Bala-Cynwyd, Pennsylvania, 19004
Chesapeake Urology Research Associates
Baltimore, Maryland, 21204
Family Cancer Center Foundation, Inc.
Bartlett, Tennessee, 38133
Texas Oncology - Beaumont, Mamie McFaddin Ward Cancer Center
Beaumont, Texas, 77702-1449
Birmingham Hematology and Oncology Associates, LLC
Bessemer, Alabama, 35022
Walter Reed National Military Medical Center
Bethesda, Maryland, 20889
Birmingham Hematology and Oncology Associates, LLC
Birmingham, Alabama, 35205
Birmingham Hematology and Oncology Associates, LLC
Birmingham, Alabama, 35211
Birmingham Hematology and Oncology Associates, LLC
Birmingham, Alabama, 35213
Birmingham Hematology and Oncology Associates, LLC
Birmingham, Alabama, 35235
New Jersey Urology, LLC
Bloomfield, New Jersey, 07003
Tufts Medical Center
Boston, Massachusetts, 02111
Steward Sr. Elizabeth's Medical Center of Boston Inc.
Boston, Massachusetts, 02135
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215
Rocky Mountain Cancer Centers
Boulder, Colorado, 80303
Manatee Medical Research Institute, LLC
Bradenton, Florida, 34205
St. Louis Cancer Care, LLP
Bridgeton, Missouri, 63044
Wheaton Franciscan Healthcare - Elmbrook Memorial Hospital
Brookfield, Wisconsin, 53045
Henry Ford Medical Center - Woodhaven
Brownstown, Michigan, 48183
Urology Health Specialists, LLC
Bryn Mawr, Pennsylvania, 19010
The Jonah Center
Buffalo, New York, 14215
Zale P. Bernstein, MD, PC
Buffalo, New York, 14215
Roswell Park Cancer Institute
Buffalo, New York, 14263-0001
Minnesota Oncology Hematology, P.A.
Burnsville, Minnesota, 55337
Northwest Georgia Oncology Centers, P.C.
Carrollton, Georgia, 30117
Northwest Georgia Oncology Centers, P.C.
Cartersville, Georgia, 30121
Raleigh Hematology Oncology Associates, D.B.A., Cancer Centers of North Carolina
Cary, North Carolina, 27518
Texas Oncology - Cedar Park
Cedar Park, Texas, 78613
Physician's Clinic of Iowa, P.C.
Cedar Rapids, Iowa, 52401
Ironwood Cancer and Research
Chandler, Arizona, 85224-5665
Charleston Hematology Oncology Associates, PA
Charleston, South Carolina, 29414
Presbyterian Hospital Cancer Center
Charlotte, North Carolina, 28204
St. Louis Cancer Care, LLP
Chesterfield, Missouri, 63017
South County Hematology/Oncology
Chula Vista, California, 91911
TriState Urologic Services PSC, Inc. dba TUG Research
Cincinnati, Ohio, 45212
Rocky Mountain Cancer Centers
Colorado Springs, Colorado, 80907
Rocky Mountain Cancer Centers
Colorado Springs, Colorado, 80909
Ellis Fischel Cancer Center - University of Missouri Health Care
Columbia, Missouri, 65203
South Carolina Oncology Associates, PA
Columbia, South Carolina, 29210
John B. Amos Cancer Center
Columbus, Georgia, 31904
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210-1280
Minnesota Oncology Hematology, P.A.
Coon Rapids, Minnesota, 55433
Wilshire Oncology Medical Group, Inc.
Corona, California, 92879
Cancer Specialists of South Texas, PA
Corpus Christi, Texas, 78412
Heartland Oncology & Hematology, PLLC
Council Bluffs, Iowa, 51503
21st Century Oncology
Crestview, Florida, 32539
Louisiana Oncology Associates
Crowley, Louisiana, 70526
Urology Clinics of North Texas, PLLC
Dallas, Texas, 75231-4482
Texas Oncology - Dallas Presbyterian Hospital
Dallas, Texas, 75231
Texas Oncology - Baylor Charles A. Sammons Cancer Center
Dallas, Texas, 75246
Henry Ford Medical Center - Fairlane
Dearborn, Michigan, 48126
Georgia Cancer Specialists - Stemmer
Decatur, Georgia, 30033
Texas Oncology - Denton South
Denton, Texas, 76210
The Urology Center of Colorado
Denver, Colorado, 80211
Rocky Mountain Cancer Centers
Denver, Colorado, 80218
Rocky Mountain Cancer Centers
Denver, Colorado, 80220
Oncology and Hematology Specialists, P.A.
Denville, New Jersey, 07830
Karmanos Cancer Institute
Detroit, Michigan, 48201
Henry Ford Hospital
Detroit, Michigan, 48202
Northwest Georgia Oncology Centers, P.C.
Douglasville, Georgia, 30134
Gwinnett Hospital System Inc. dba Center for Cancer Care
Duluth, Georgia, 30096
Cancer Centers of Southwest Oklahoma
Duncan, Oklahoma, 73533
Regional Cancer Care, P.A.
Durham, North Carolina, 27704
Duke University Medical Center - Duke South Clinics
Durham, North Carolina, 27710
North Shore Hematology/Oncology Associates
East Setauket, New York, 11733
Minnesota Oncology Hematology, P.A.
Edina, Minnesota, 55435-2150
Texas Oncology - El Paso Cancer Treatment Center Grandview
El Paso, Texas, 79902
Texas Oncology - El Paso Cancer Treatment Center Gateway
El Paso, Texas, 79915
Texas Oncology - El Paso Cancer Treatment Center Joe Battle
El Paso, Texas, 79939
Elkhart Clinic
Elkhart, Indiana, 46514
Elkhart General Hospital
Elkhart, Indiana, 46514
Urology Specialists of Southern California
Encino, California, 91436-2140
The Regional Cancer Center
Erie, Pennsylvania, 16505
Urological Associates, Inc.
Evansville, Indiana, 47714
Karmanos Cancer Institute at Farmington Hills
Farmington Hills, Michigan, 48334
Georgia Cancer Specialists - Fayetteville
Fayetteville, Georgia, 30215
Cape Fear Valley Health System
Fayetteville, North Carolina, 28304
Integrated Community Oncology Network
Fleming Island, Florida, 32003
21st Century Oncology
Fort Myers, Florida, 33907
Fort Wayne Medical Oncology and Hematology, Inc.
Fort Wayne, Indiana, 46845
Texas Oncology - Fort Worth 12th Avenue
Fort Worth, Texas, 76104
Texas Oncology - Southwest Fort Worth
Fort Worth, Texas, 76132
Robert A. Moss, M.D., F.A.C.P., Inc
Fountain Valley, California, 92708
Wheaton Franciscan Healthcare - Reiman Cancer Center
Franklin, Wisconsin, 53132
Queens Medical Associates
Fresh Meadows, New York, 11366
Minnesota Oncology Hematology, P.A.
Fridley, Minnesota, 55432
Carolina Urology Partners
Gastonia, North Carolina, 28054-3456
The Jones Clinic, PC
Germantown, Tennessee, 38138
Gettysburg Cancer Center
Gettysburg, Pennsylvania, 17325
Palo Verde Cancer Specialists
Glendale, Arizona, 85304
Pacific Shores Medical Group
Glendale, California, 91204
Wilshire Oncology Medical Group, Inc.
Glendora, California, 91741
Western Oncology/Hematology Associates, PC
Golden, Colorado, 80401
Weatern Regional Medical Center / Cancer Treatment Centers of America
Goodyear, Arizona, 85338
Myron I Murdock MD LLC
Greenbelt, Maryland, 20770
Comprehensive Cancer Centers of Nevada
Henderson, Nevada, 89014
Comprehensive Cancer Centers of Nevada
Henderson, Nevada, 89052
Comprehensive Cancer Centers of Nevada
Henderson, Nevada, 89074
UTHealth Oncology, Memorial Hermann Cancer Center
Houston, Texas, 77030
Memorial Hennann Hosptial - Southwest Cancer Center
Houston, Texas, 77074
Florida Cancer Specialists, PL
Hudson, Florida, 34667
Memorial Hennann Hospital - Northeast Cancer Center
Humble, Texas, 77338
Presbyterian Hospital Huntersville
Huntersville, North Carolina, 28078
Pacific Shores Medical Group
Huntington Beach, California, 92648
Clearview Cancer Institute
Huntsville, Alabama, 35805
Integrated Community Oncology Network
Jacksonville, Florida, 32204
Integrated Community Oncology Network
Jacksonville, Florida, 32207
Cancer Specialists of North Florida
Jacksonville, Florida, 32256
Integrated Community Oncology Network
Jacksonville, Florida, 32258
Integrated Community Oncology Network
Jacksonville Beach, Florida, 32250
Metropolitan Urology Clinical Research
Jeffersonville, Indiana, 47130
Joliet Oncology-Hematology Associates, Ltd.
Joliet, Illinois, 60435
Urological Surgeons of Illinois
Kankakee, Illinois, 60901
Saint Luke's Cancer Institute, Saint Luke's Hospital
Kansas City, Missouri, 64111
Texas Oncology - Kyle
Kyle, Texas, 78640
UCSD Medical Center - La Jolla
La Jolla, California, 92037
UCSD Moores Cancer Center
La Jolla, California, 92093-0820
Moores UCSD Cancer Center
La Jolla, California, 92093
Cancer Center Oncology Medical Group
La Mesa, California, 91942
Indiana University Health La Porte Hospital
La Porte, Indiana, 46350
Wilshire Oncology Medical Group, Inc.
La Verne, California, 91750
Louisiana Oncology Associates
Lafayette, Louisiana, 70508
Watson Clinic LLP, Center for Cancer Care & Research, Clark & Daughtrey Medical Group, PA
Lakeland, Florida, 33805
Rocky Mountain Cancer Centers
Lakewood, Colorado, 80228
Urological Associates of Lancaster
Lancaster, Pennsylvania, 17604
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, 89128
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, 89148
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, 89169
Gwinnett Hospital System Inc. dba Center for Cancer Care
Lawrenceville, Georgia, 30046
Cancer Centers of Southwest Oklahoma
Lawton, Oklahoma, 73505
Dartmouth Hitchcock Medical Center, Norris Cotton Cancer Center
Lebanon, New Hampshire, 03756
Texas Oncology - Lewisville
Lewisville, Texas, 75067
Nebraska Hematology-Oncology, PC
Lincoln, Nebraska, 68506
Southeast Nebraska Hematology & Oncology Consultants, PC / Southeast Nebraska Cancer Center
Lincoln, Nebraska, 68510
Southeast Nebraska Hematology & Oncology Consultants, PC / Southeast Nebraska Cancer Center
Lincoln, Nebraska, 68516
Little Rock Hematology Oncology: A Division of CARTI
Little Rock, Arkansas, 72205
Rocky Mountain Cancer Centers
Littleton, Colorado, 80120-4413
Rocky Mountain Cancer Centers
Lone Tree, Colorado, 80124
Pacific Shores Medical Group
Long Beach, California, 90813
Rocky Mountain Cancer Centers
Longmont, Colorado, 80501
Pacific Shores Medical Group
Los Alamitos, California, 90720
UCLA Institute of Urologic Oncology, UCLA Medical Center
Los Angeles, California, 90024
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033
Tower Urology
Los Angeles, California, 90048
Jewish Hospital & St. Mary's Healthcare
Louisville, Kentucky, 40245
Northwest Florida Hematology Oncology PA
Lynn Haven, Florida, 32444
Georgia Cancer Specialists - Macon
Macon, Georgia, 31217
Minnesota Oncology Hematology, P.A.
Maplewood, Minnesota, 55109
Georgia Cancer Specialists - Kennestone
Marietta, Georgia, 30060
Northwest Georgia Oncology Centers, P.C.
Marietta, Georgia, 30060
Urology Enterprises
Marietta, Georgia, 30060
Prostate Oncology Speciality Inc.
Marina del Rey, California, 90292
Matthews Hematology Oncology Associates
Matthews, North Carolina, 28105
Presbyterian Hospital Matthews
Matthews, North Carolina, 28105
Family Cancer Center Foundation, Inc.
Memphis, Tennessee, 38119
Family Cancer Center Foundation, Inc.
Memphis, Tennessee, 38120
The West Clinic
Memphis, Tennessee, 38120
Advanced Medical Specialties
Miami, Florida, 33143
Advanced Medical Specialties
Miami, Florida, 33176
Mount Sinai Comprehensive Cancer Center
Miami Beach, Florida, 33140
SouthWest Urology
Middleburg Heights, Ohio, 44130
Wheaton Franciscan Healthcare - St. Joseph's Hospital
Milwaukee, Wisconsin, 53210
Wheaton Franciscan Healthcare - St. Francis Hospital
Milwaukee, Wisconsin, 53215
Minnesota Oncology Hematology, P.A.
Minneapolis, Minnesota, 55404
University Of Minnesota
Minneapolis, Minnesota, 55455
Saint Joseph Regional Medical Center
Mishawaka, Indiana, 46545
Lake Norman Hematology Oncology Specialists
Mooresville, North Carolina, 28117
Hematology-Oncology Associates of Northern NJ, PA; Carol G. Simon Cancer Center
Morristown, New Jersey, 07962
Delaware Valley Urology, LLC
Mount Laurel, New Jersey, 08054
Tri Valley Urology Medical Group
Murrieta, California, 92562
Carolina Urologic Research Center
Myrtle Beach, South Carolina, 29572
21st Century Oncology
Naples, Florida, 34102
Premier Oncology
Naples, Florida, 34102
Tennessee Oncology, Centennial Medical Center
Nashville, Tennessee, 37203
Urology Associates, P.C.
Nashville, Tennessee, 37209
Vanderbilt University Medical Center
Nashville, Tennessee, 37232
The Jones Clinic, PC
New Albany, Mississippi, 38652
Coastal Carolina Health Care, PA, dba New Bern Cancer Care
New Bern, North Carolina, 28562
Grove Hill Clinical Research, Grove Hill Medical Center, Urology Center of Grove Hill
New Britain, Connecticut, 06052
Yale Urology
New Haven, Connecticut, 06511
Louisiana Oncology Associates
New Iberia, Louisiana, 70560
Tulane University Health Sciences Center
New Orleans, Louisiana, 70112
Florida Cancer Specialists, PL
New Port Richey, Florida, 34655
NYU Clinical Cancer Center
New York, New York, 10016
NYU Langone Medical Center
New York, New York, 10016
Oncology Specialists, S.C.
Niles, Illinois, 60714
Lakeland Hospital
Niles, Michigan, 49120
Urology of Virginia / SMG
Norfolk, Virginia, 23502
Mid-Illinois Hematology & Oncology Associates, LTD
Normal, Illinois, 61761
Integrated Medical Professionals
North Hills, New York, 11042
Norwalk Hospital
Norwalk, Connecticut, 06856
Eastern Connecticut Hematology and Oncology Associates
Norwich, Connecticut, 06360
Henry Ford Medical Center - Columbus Center
Novi, Michigan, 48377
Ocala Oncology Center
Ocala, Florida, 33471
North County Oncology Medical Group, Inc.
Oceanside, California, 92056
MedStar Montgomery Medical Center
Olney, Maryland, 20832
Oncology Hematology West, PC dba Nebraska Cancer Specialists
Omaha, Nebraska, 68130
Urology Cancer Center & GU Research Network
Omaha, Nebraska, 68130
Louisiana Oncology Associates
Opelousas, Louisiana, 70570
Hematology-Oncology Medical Group of Orange County, Inc.
Orange, California, 92868
Medical Oncology Care Associates (MOCA)
Orange, California, 92868
The Center for Cancer Prevention and Treatment, St. Joseph Hospital
Orange, California, 92868
Atlantic Urological Associates
Orange City, Florida, 32763
Integrated Community Oncology Network
Orange Park, Florida, 32073
Kansas City Urology Care
Overland Park, Kansas, 66211
Family Cancer Center Foundation, Inc.
Oxford, Mississippi, 38655
PMK Medical Group, Inc., DBA Ventura County Hematology Oncology Specialists
Oxnard, California, 93030
Integrated Community Oncology Network
Palatka, Florida, 32177
Oncology Specialists, S.C.
Park Ridge, Illinois, 60068
Advanced Urology, PC
Parker, Colorado, 80134
Rocky Mountain Cancer Centers
Parker, Colorado, 80138
Wilshire Oncology Medical Group, Inc.
Pasadena, California, 91105
Sacred Heart Medical Oncology Groupl
Pensacola, Florida, 32504
UPMC Cancer Center / Hillman Cancer Centerl
Pittsburgh, Pennsylvania, 15232
Michiana Hematology Oncology, P. C.
Plymouth, Indiana, 46563
Wilshire Oncology Medical Group, Inc.
Pomona, California, 91767
Northwest Cancer Specialists, P.C.
Portland, Oregon, 97213-2982
Providence Cancer Center Oncology and Hematology Care
Portland, Oregon, 97213
Northwest Cancer Specialists, P.C.
Portland, Oregon, 97225
Northwest Cancer Specialists, P.C.
Portland, Oregon, 97227
Premier Medical Group of the Hudson Valley
Poughkeepsie, New York, 12601
Harrison Poulsbo Hematology & Oncology
Poulsbo, Washington, 98370
Rocky Mountain Cancer Centers
Pueblo, Colorado, 81008
Raleigh Hematology Oncology Associates, D.B.A., Cancer Centers of North Carolina
Raleigh, North Carolina, 27607
Raleigh Hematology Oncology Associates, D.B.A., Cancer Centers of North Carolina
Raleigh, North Carolina, 27614
Wilshire Oncology Medical Group, Inc.
Rancho Cucamonga, California, 91730
Hubert H. Humphrey Cancer Center
Robbinsdale, Minnesota, 55422
James P. Wilmot Cancer Center
Rochester, New York, 14642
Harbin Clinic
Rome, Georgia, 30165
Sutter Roseville Medical Center
Roseville, California, 95677
Texas Oncology - Seton-Williamson
Round Rock, Texas, 78665
Texas Oncology - Round Rock
Round Rock, Texas, 78681
Sutter Cancer Center / Sacramento Center for Hematology and Medical Oncology
Sacramento, California, 95816
Sutter Memorial Hospital
Sacramento, California, 95819-3223
Integrated Community Oncology Network
Saint Augustine, Florida, 32086
Michgan Institute of Urology, PC
Saint Clair Shores, Michigan, 48081
Lakeland Hospital
Saint Joseph, Michigan, 49085-2158
Marie Yeager Cancer Center
Saint Joseph, Michigan, 49085
Minnesota Oncology Hematology, P.A.
Saint Paul, Minnesota, 55102-2389
Huntsman Cancer Hospital
Salt Lake City, Utah, 84112
Urology San Antonio Research
San Antonio, Texas, 78229
Oncology San Antonio Research, LLC
San Antonio, Texas, 78240
UCSD Medical Center - Hillcrest
San Diego, California, 92103
Genesis Research
San Diego, California, 92123
Medical Oncology Associates
San Diego, California, 92123
Sharp Clinical Oncology Research
San Diego, California, 92123
Sharp Rees-Stealy
San Diego, California, 92123
Texas Oncology - San Marcos
San Marcos, Texas, 78666
Georgia Cancer Specialists - Northside
Sandy Springs, Georgia, 30342
Edward Alexson, MD, Inc.
Santa Ana, California, 92705
New Mexico Cancer Care Associates
Santa Fe, New Mexico, 87505
Adult and Pediatric Urology
Sartell, Minnesota, 56377
21st Century Oncology
Scottsdale, Arizona, 85251
Pinnacle Oncology Hematology, Oncology Research Associates, PLLC
Scottsdale, Arizona, 85258
Scranton Hematology Oncology
Scranton, Pennsylvania, 18510
Virginia Mason Medical Center
Seattle, Washington, 98101
Seattle Cancer Care Alliance
Seattle, Washington, 98109
University of Washington
Seattle, Washington, 98109
Northwest Louisiana Oncology Associates Of Highland Clinic
Shreveport, Louisiana, 71105
Regional Urology, LLC
Shreveport, Louisiana, 71106
Avera Cancer Institute, Avera Medical Group Oncology and Hematology
Sioux Falls, South Dakota, 57105
Gwinnett Hospital System Inc. dba Center for Cancer Care
Snellville, Georgia, 30078
Memorial Hospital of South Bend
South Bend, Indiana, 46601
Northern Indiana Cancer Research Consortium, Michiana Hematology Oncology, P.C.
South Bend, Indiana, 46601
Family Cancer Center Foundation, Inc.
Southaven, Mississippi, 38671
Sparta Cancer Center
Sparta, New Jersey, 07871
Urology Center of Spartanburg
Spartanburg, South Carolina, 29303
Medical Oncology Associates, PS
Spokane, Washington, 99208
Oregon Urology Institute
Springfield, Oregon, 97477
St. Louis Cancer Care, LLP
St Louis, Missouri, 63127
Comprehensive Cancer Care
St Louis, Missouri, 63141
The Stamford Hospital
Stamford, Connecticut, 06902
Staten Island Urological Research, PC
Staten Island, New York, 10304
Georgia Cancer Specialists - Stockbridge
Stockbridge, Georgia, 30281
Stockton Hematology Oncology Medical Group
Stockton, California, 95204
Associated Medical Professionals of New York, PLLC
Syracuse, New York, 13210
About this study
The purpose of this study is to further quantify the risk of cerebrovascular events (CVEs) following sipuleucel-T (PROVENGE®) therapy, and to follow all subjects for survival.
Read the detailed description
Subjects will receive product as described in the sipuleucel-T approved label. The registry will be strictly observational and thus no additional clinical visits or laboratory tests will be conducted beyond normal clinical practice. Investigators will be asked to record information that becomes available in the normal course of clinical management.
- Conditions
- Advanced Prostate Cancer, Prostatic Neoplasms
- Being tested
- sipuleucel-T
- Medical subject headings
- Prostatic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
sipuleucel-TBiological
Also called PROVENGE, APC8015
Each dose of sipuleucel-T contains a minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF. The recommended course of therapy for sipuleucel-T is 3 complete doses, given at approximately 2-week intervals.
| Study group | Role | What they receive |
|---|---|---|
| sipuleucel-T | Not described Receives: Biological: sipuleucel-T |
What is being measured
The primary outcome is the main question the study is designed to answer.
To Further Quantify the Risk of Cerebrovascular Events Following Sipuleucel-T Therapy for All Subjects
The incidence rate of CVEs (cardiovascular events) was estimated as the number of new events per 100 patient years of follow-up in the overall sample of men with advanced-stage or metastatic prostate cancer and in men with or without castration.
Measured: Every 3 months for a minimum of 3 years
Secondary outcomes (1)
Survival
To quantify survival by estimating the median time of survival in all subjects using the Kaplan-Meier method.
Measured: Every 3 months for a minimum of 3 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Mar 2011 (estimated)
- Study start27 Jan 2011
- Primary completion17 Jan 2017
- Study completion17 Jan 2017
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Advanced Prostate CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 1,976 participants (actual)
Sponsor and investigators
- Lead sponsor
- Dendreon
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Bruce Brown, MD, Study director, Dendreon Pharmaceuticals
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01306890
- Sponsor's protocol ID
- P10-3
- Acronym
- PROCEED
- Status last verified
- Mar 2019
- First submitted
- 28 Feb 2011
- Last updated
- 7 Jun 2019
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
Publications
Wei XX, Kwak L, Hamid A, He M, Sweeney C, Flanders SC, Harmon M, Choudhury AD. Outcomes in men with metastatic castration-resistant prostate cancer who received sipuleucel-T and no immediate subsequent therapy: experience at Dana Farber and in the PROCEED Registry. Prostate Cancer Prostatic Dis. 2022 Feb;25(2):314-319. doi: 10.1038/s41391-022-00493-x. Epub 2022 Feb 10.
PubMed 35145218Sartor O, Armstrong AJ, Ahaghotu C, McLeod DG, Cooperberg MR, Penson DF, Kantoff PW, Vogelzang NJ, Hussain A, Pieczonka CM, Shore ND, Quinn DI, Small EJ, Heath EI, Tutrone RF, Schellhammer PF, Harmon M, Chang NN, Sheikh NA, Brown B, Freedland SJ, Higano CS. Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry. Prostate Cancer Prostatic Dis. 2020 Sep;23(3):517-526. doi: 10.1038/s41391-020-0213-7. Epub 2020 Feb 28.
PubMed 32111923
Study at a glance
From the registry record, last updated by the sponsor on 7 Jun 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
- ClinicalTrials.gov ID
- NCT01306890
- Acronym / sponsor ID
- PROCEED / P10-3
- Conditions
- Advanced Prostate Cancer, Prostatic Neoplasms
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 1,976 participants (actual)
- Lead sponsor
- DendreonIndustry (pharma, biotech, devices)
- Study start
- 27 Jan 2011 (actual)
- Primary completion
- 17 Jan 2017 (actual)
- Study completion
- 17 Jan 2017 (actual)
- First posted
- 2 Mar 2011 (estimated)
- Results
- Posted 7 Jun 2019
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to further quantify the risk of cerebrovascular events (CVEs) following sipuleucel-T (PROVENGE®) therapy, and to follow all subjects for survival.
Detailed description
Subjects will receive product as described in the sipuleucel-T approved label. The registry will be strictly observational and thus no additional clinical visits or laboratory tests will be conducted beyond normal clinical practice. Investigators will be asked to record information that becomes available in the normal course of clinical management.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| sipuleucel-T | – | Biological: sipuleucel-T |
Who may qualify
- Ages
- 18 years and older
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Men at least 18 years of age that have advanced prostate cancer that is treated with sipuleucel-T
Key inclusion criteria (3 listed)
- subjects must be at least 18 years of age
- subjects with advanced prostate cancer who will receive sipuleucel-T or who underwent their first leukapheresis for manufacture of sipuleucel-T ≤ 6 months prior to enrollment
- subjects must understand and sign an informed consent form
Key exclusion criteria (1 listed)
- none
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| sipuleucel-TAlso: PROVENGE, APC8015Each dose of sipuleucel-T contains a minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF. The recommended course of therapy for sipuleucel-T is 3 complete doses, given at approximately 2-week intervals. | Biological | sipuleucel-T |
Primary outcome
To Further Quantify the Risk of Cerebrovascular Events Following Sipuleucel-T Therapy for All Subjects
Time frame: Every 3 months for a minimum of 3 years
The incidence rate of CVEs (cardiovascular events) was estimated as the number of new events per 100 patient years of follow-up in the overall sample of men with advanced-stage or metastatic prostate cancer and in men with or without castration.
1 secondary outcome
Survival
Time frame: Every 3 months for a minimum of 3 years
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Jun 2019.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 35145218Wei XX, Kwak L, Hamid A, He M, Sweeney C, Flanders SC, Harmon M, Choudhury AD. Outcomes in men with metastatic castration-resistant prostate cancer who received sipuleucel-T and no immediate subsequent therapy: experience at Dana Farber and in the PROCEED Registry. Prostate Cancer Prostatic Dis. 2022 Feb;25(2):314-319. doi: 10.1038/s41391-022-00493-x. Epub 2022 Feb 10.
- Derived from this study: PubMed 32111923Sartor O, Armstrong AJ, Ahaghotu C, McLeod DG, Cooperberg MR, Penson DF, Kantoff PW, Vogelzang NJ, Hussain A, Pieczonka CM, Shore ND, Quinn DI, Small EJ, Heath EI, Tutrone RF, Schellhammer PF, Harmon M, Chang NN, Sheikh NA, Brown B, Freedland SJ, Higano CS. Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry. Prostate Cancer Prostatic Dis. 2020 Sep;23(3):517-526. doi: 10.1038/s41391-020-0213-7. Epub 2020 Feb 28.
Related trials for Advanced Prostate Cancer
RecruitingPhase 1/2
Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Active, not recruitingPhase 1/2
Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...
Colorectal Neoplasms, Breast Neoplasms
RecruitingPhase 2
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma
RecruitingPhase 2
Evaluating In Home Cancer Therapy Versus In Clinic Cancer Therapy in Black Men With Locally Advanced, Biochemically Recurrent and Metastatic Prostate Cancer
Biochemically Recurrent Prostate Carcinoma, Locally Advanced Prostate Carcinoma
Active, not recruitingPhase 1
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
Advanced Solid Tumor
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Bruce Brown, MD study director
Dendreon Pharmaceuticals
333 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Advanced Prostate Cancer and Prostatic Neoplasms, run by Dendreon at 333 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 7 Jun 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 333 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 7 Jun 2019). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To Further Quantify the Risk of Cerebrovascular Events Following Sipuleucel-T Therapy for All Subjects (time frame: Every 3 months for a minimum of 3 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01306890, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Jun 2019.